|
Abstract:
Continued development of an 'infection-permissive' neuraminidase-specific vaccine has proceeded. Such a vaccine may be produced either by tailor-making a recombinant virus containing the neuraminidase of the current subtype of influenza virus coupled with an irrelevant hemagglutinin or by isolation of the neuraminidase directly from the virus. Vaccine trials have compared the immune response of a neuraminidase-specific vaccine employing the recombinant X-38 (Heq1N2) with that of a conventional bispecific vaccine, X-37 (H3N2). A superior antibody response to neuraminidase was observed when the enzyme was coupled with the 'irrelevant' hemagglutinin in the X-38 vaccine as compared with the conventional vaccine. An unexpected finding was the induction of anti-H3 heterotypic antibody by the X-38 vaccine possessing the 'irrelevant' hemagglutinin. Techniques for viral protein purification have been improved and have shown that hemagglutinin as a dimer is immunogenic.
| Description: |
Annual progress rept. 31 Jul 75-1 Aug 76 |
| Pages: |
34 |
| Report Date: |
SEP 1976 |
| Contract Number: |
DADA1769C9137 |
| Report Number: |
B499410 |
Report Unavailable |
| This title is unavailable from Storming Media. We do not know when it might be available, if at all. We list the report on our site for bibliographic completeness, to help our users know what other work has been performed in this field. Please note that as with all titles on this site, we do not have contact information for any of the authors. Nor can we give any suggestions on how one might obtain this report. |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
